Summary of Significant Accounting Policies (Tables)

9 Months Ended

Mar. 31, 2018

Summary of Significant Accounting Policies

Schedule of the Company's net sales by medical indication

(In thousands)	For the Three Months Ended March 31,					For the Nine Months Ended March 31,
Medical Indication	2018		2017			2018		2017
Antibiotic	$	3,801	$	4,474		$	10,701	$	13,047
Anti-Psychosis	9,336		14,433			47,127		47,119
Cardiovascular	18,514		14,815			39,955		39,484
Central Nervous System	8,395		11,124			24,137		32,028
Gallstone	3,828		11,157			15,674		37,465
Gastrointestinal	16,562		19,441			46,171		56,470
Glaucoma	875		4,868			5,706		15,962
Migraine	12,888		7,043			43,387		22,066
Muscle Relaxant	3,299		3,673			10,309		10,208
Pain Management	6,594		6,085			18,483		20,132
Respiratory	2,324		4,256			6,200		9,426
Thyroid Deficiency	69,975		44,999			185,983		130,267
Urinary	33		2,619			5,870		12,413
Other	12,376		14,555			38,178		36,870
Contract manufacturing revenue	5,586		2,178			15,771		15,266
Net sales	174,386		165,720			513,652		498,223
Settlement agreement	—		(4,000		)	—		(4,000		)
Total net sales	$	174,386	$	161,720		$	513,652	$	494,223

Summary of products which accounted for at least 10% of total net sales

	For the Three Months Ended March 31,				For the Nine Months Ended March 31,
	2018		2017		2018		2017
Product 1	40	%	28	%	36	%	26	%

Summary of customers which accounted for at least 10% of total net sales

	For the Three Months Ended March 31,				For the Nine Months Ended March 31,
	2018		2017		2018		2017
Customer A	32	%	27	%	27	%	28	%
Customer B	15	%	23	%	18	%	21	%